TocIlizumab in Late/Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients

This multi-center study is an investigator-driven randomized controlled parallel group open-label clinical trial designed to evaluate the efficacy of addition of anti-IL-6 antibody tocilizumab (TCZ) to the standard of care (SOC) treatment as compared to the SOC alone in reducing the decline of graft function in kidney transplant recipients with late or chronic antibody-mediated rejection (AMR). A total of 50 recipients will be allocated to receive either TCZ (n=25) added to the standard of care (SOC) or SOC alone (n=25) for a period of 24 months. Patients will be followed for an additional 12 months. Protocol kidney graft biopsies will be performed at 12 and 24 months. The primary outcome is the mean rate of change in graft function as assessed by estimated glomerular filtration rate (eGFR) slope from baseline to 24 months after start of treatment.

NCT Number	NCT04561986
Lead Sponsor	Vastra Gotaland Region Collaborators: Karolinska University Hospital, Uppsala University Hospital, The Swedish Research Council, Hospital del Mar, Hospital Universitario Doctor Peset, Complexo Hospitalario Universitario de A Coruña
Conditions	Antibody-mediated Rejection
Enrollment	50 participants
Start Date	2022-02-01
Primary Completion	2028-06 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-10